Digene to Present At Piper Jaffray Health Care Conference
November 21 2006 - 12:14PM
PR Newswire (US)
GAITHERSBURG, Md., Nov. 21 /PRNewswire-FirstCall/ -- Digene
Corporation (NASDAQ:DIGE), today announced that Evan Jones,
Chairman and Chief Executive Officer, and Joseph Slattery, Chief
Financial Officer, will be presenting at the Piper Jaffray Health
Care Conference on Wednesday, November 29, 2006 at 2:30 p.m.
Eastern Standard Time. This conference will be held at The Pierre
Hotel, New York, NY. A link to Piper Jaffray's live webcast and
recording of Digene's presentation will be available on the
Company's website, http://www.digene.com/. The recording of
Digene's presentation will be available beginning approximately
three hours after the live presentation ends, and will be archived
until December 28, 2006. About Digene Digene Corporation
(NASDAQ:DIGE), based in Gaithersburg, MD, develops, manufactures
and markets proprietary DNA and RNA testing systems for the
screening, monitoring and diagnosis of human diseases - with a
focus on women's cancers and infectious diseases. The company's hc2
High-Risk HPV DNA Test(R) is the only test for human papillomavirus
approved by the U.S. Food and Drug Administration (FDA), for both
follow-up evaluation in women with inconclusive Pap results and for
primary adjunctive screening with the Pap test in women age 30 and
older. For primary adjunctive screening, it is marketed as both The
Digene HPV Test and the DNAwithPap(R) Test. These brand names do
not refer to the Digene product that tests for several types of the
virus commonly referred to as "low-risk HPV," which are not
associated with cervical cancer. For more information, visit
http://www.thehpvtest.com/. Digene's HPV test is also CE-marked in
Europe both routine, primary screening and follow-up evaluation of
women with inconclusive Paps. It is marketed in more than 40
countries worldwide. In addition, Digene's product portfolio
includes DNA tests for the detection of other sexually transmitted
infections, including Chlamydia and gonorrhea, as well as tests for
blood viruses. For more information, visit the company's Web site,
http://www.digene.com/. Journalists may contact Pam Rasmussen,
(301) 944-7196. DATASOURCE: Digene Corporation CONTACT: Investors -
Albert Fleury, Investor Relations, Digene Corporation,
+1-301-944-7000; Investor Relations - Evan Smith of Financial
Dynamics, +1-212-850-5606; Media -Pam Rasmussen, Digene,
+1-301-944-7196; or Sean Leous, Financial Dynamics, +1-212-850-5755
Web site: http://www.digene.com/
Copyright
Digene (NASDAQ:DIGE)
Historical Stock Chart
From Feb 2025 to Mar 2025
Digene (NASDAQ:DIGE)
Historical Stock Chart
From Mar 2024 to Mar 2025